 
BioStem Technologies Delivers Solid Q3 Results, Expands Clinical Footprint, and Targets Nasdaq Uplisting with a $25.50 Zacks Price Target. BioStem Technologies (OTC: BSEM) reported a resilient Q3 2025, generating $10.5 million in net revenue, $0.8 million in GAAP net income, and achieving its seventh consecutive quarter of positive adjusted EBITDA, coming in at $2.7 million. Despite modest pricing-related revenue pressure, the company continues to demonstrate financial strength, supported by an 88.5% gross margin and a $27.2 million cash balance. Zacks Small Cap Research maintains a $25.50 price target, reflecting confidence in BioStem’s operational performance, expanding revenue channels, and maturing clinical portfolio. Clinically, BioStem’s BioREtain® allografts are gaining meaningful traction. A published Level 1 randomized trial in diabetic foot ulcers showed significantly superior outcomes versus standard care, reinforcing competitive differentiation and supporting expanded reimbursement visibility. With new penetration into VA and Medicaid programs, growing hospital and ASC opportunities, and a Nasdaq uplisting targeted for mid-2026, BioStem is positioning itself for long-term growth in a MedTech market that continues to benefit from strong demand, aging demographics, and underpenetrated regenerative-care needs. See why BSEM may be well-timed for investors seeking exposure to high-growth MedTech.
This message is a paid advertisement for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency and Huge Alerts. American Consumer News, LLC dba MarketBeat receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $12,600. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Sideways Frequency or Huge Alerts. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on Huge Alerts' website for additional information about the relationship between Huge Alerts and BioStem Technologies Inc. (OTC: BSEM). | 
0 Response to "BSEM: Analysts Say $25.50 Target on this Small Cap!"
Post a Comment